Expansion of sales of radiology products and transferred products
First written in FY2016-Q3. 23 of 27 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1AdvancedAnnual report
「For biosimilars, in addition to focusing on ustekinumab BS subcutaneous injection 45 mg “F,” a psoriasis treatment launched in May 2024, the company submitted applications for marketing approval for 1 product in September 2024 and 2 products in October 2024, and is moving forward with further expansion of its biosimilars business.」
For new products in acute-care medicine, the disclosure states that 「ウステキヌマブBS皮下注45mg「F」」 began sales in May 2024 and that applications were submitted for approval of 3 additional biosimilar products. - FY2024-Q2AdvancedAnnual report
「Sales for the second quarter cumulative period increased steadily for core women’s healthcare products, principally Femeno capsules 100 mg and Doxil injection 20 mg, as well as Iopamidol injection, a nonionic urographic and angiographic contrast medium. As a result, sales for the second quarter cumulative period were ¥21,388 million, up 11.2% year on year, and sales for the second quarter cumulative period were ¥21,388 million, up 11.2% year on year.」
The disclosure states that 「イオパミドール注」 in radiology grew steadily, indicating specific progress in expanding sales of existing contrast agents. - FY2024-Q1RestatedAnnual report
「In addition to the nonionic urinary tract and vascular contrast agent 「イオパミドール注」 and the nonionic contrast agent 「イオヘキソール注」 in radiology, we are preparing to begin marketing new products in acute-care medicine: the antineoplastic agent 「レナリドミドカプセル」 for hematology, scheduled for January 2024; the antiarrhythmic agent 「ランジオロール塩酸塩点滴静注用」, scheduled for March 2024; and 「ウステキヌマブBS皮下注」, used to treat plaque psoriasis and psoriatic arthritis when existing treatments are insufficient, scheduled for May 2024.」
While continuing to focus on sales of radiology contrast agents, we are preparing to market new products in acute-care medicine. - FY2023-Q3RestatedAnnual report
「In radiology, an acute-care medical field, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「イオパミドール注」 and the nonionic contrast agent 「イオヘキソール注」.」
In radiology, we continue to focus on sales of 「イオパミドール注」 and 「イオヘキソール注」 to further expand their market shares. - FY2023-Q2RestatedAnnual report
「In radiology, an acute-care medical field, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「イオパミドール注」 and the nonionic contrast agent 「イオヘキソール注」.」
In radiology, we continue to focus on sales of 「イオパミドール注」 and 「イオヘキソール注」 to further expand their market shares. - FY2023-Q1RestatedAnnual report
「In radiology, an acute-care medical field, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「イオパミドール注」 and the nonionic contrast agent 「イオヘキソール注」.」
In radiology, we continue to focus on sales of 「イオパミドール注」 and 「イオヘキソール注」 to further expand their market shares. - FY2022RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「イオパミドール注」 and the nonionic contrast agent 「イオヘキソール注」.」
We continue to pursue our policy of focusing on expanding the market shares of 「イオパミドール注」 and 「イオヘキソール注」 in radiology. - FY2022-Q3RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「イオパミドール注」 and the nonionic contrast agent 「イオヘキソール注」.」
We continue to expand our share of the radiology market, centered on 「イオパミドール注」 and 「イオヘキソール注」. - FY2022-Q2RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「イオパミドール注」 and the nonionic contrast agent 「イオヘキソール注」.」
We continue to pursue further market-share expansion for 「イオパミドール注」 and 「イオヘキソール注」 in radiology. - FY2022-Q1RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「イオパミドール注」 and the nonionic contrast agent 「イオヘキソール注」.」
In radiology, we continue to focus on sales of 「イオパミドール注」 and 「イオヘキソール注」 to further expand their market shares. - FY2021RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「イオパミドール注」 and the nonionic contrast agent 「イオヘキソール注」.」
We continue to pursue further market-share expansion for contrast agents in radiology, identifying the products concerned. - FY2021-Q3RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「イオパミドール注」 and the nonionic contrast agent 「イオヘキソール注」.」
In radiology, we continue to focus on sales of 「イオパミドール注」 and 「イオヘキソール注」 to further expand their market shares. - FY2021-Q2RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「イオパミドール注」 and the nonionic contrast agent 「イオヘキソール注」.」
In radiology, we continue to focus on sales of 「イオパミドール注」 and 「イオヘキソール注」 to further expand their market shares. - FY2021-Q1RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「オイパロミン注」 and the nonionic contrast agent 「イオパーク注」.」
In radiology, we continue to focus on sales of 「オイパロミン注」 and 「イオパーク注」 to further expand their market shares. - FY2020-Q3RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「オイパロミン注」 and the nonionic contrast agent 「イオパーク注」.」
In radiology, we continue to focus on sales of 「オイパロミン注」 and 「イオパーク注」 to further expand their market shares. - FY2020-Q2RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「オイパロミン注」 and the nonionic contrast agent 「イオパーク注」.」
In radiology, we continue to focus on sales of 「オイパロミン注」 and 「イオパーク注」 to further expand their market shares. - FY2019-Q3RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「オイパロミン注」 and the nonionic contrast agent 「イオパーク注」.」
In radiology, we continue to focus on sales of 「オイパロミン注」 and 「イオパーク注」 to further expand their market shares. - FY2019-Q2RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「オイパロミン注」 and the nonionic contrast agent 「イオパーク注」.」
In radiology, we continue to focus on sales of 「オイパロミン注」 and 「イオパーク注」 to further expand their market shares. - FY2019-Q1RestatedAnnual report
「In radiology, we are focusing on further expanding the market shares of the nonionic urinary tract and vascular contrast agent 「オイパロミン注」 and the nonionic contrast agent 「イオパーク注」.」
We continue to focus on sales of 「オイパロミン注」 and 「イオパーク注」 in order to further expand their market shares in radiology. - FY2018-Q3RestatedAnnual report
「In radiology, we are focusing on sales of the X-ray generic contrast agents 「オイパロミン注」 and 「イオパーク注」, which we have marketed for some time, 「オプチレイ注」, for which approval to add an indication was obtained last year, and the MRI contrast agent 「マグネスコープ静注」, among others.」
We continue to focus on sales of radiology products, including 「オイパロミン注」, 「イオパーク注」, 「オプチレイ注」 and 「マグネスコープ静注」. - FY2018-Q2RestatedAnnual report
「In radiology, we are focusing on sales of the X-ray generic contrast agents 「オイパロミン注」 and 「イオパーク注」, which we have marketed for some time, 「オプチレイ注」, for which approval to add an indication was obtained last year, and the MRI contrast agent 「マグネスコープ静注」, among others.」
We continue to focus on sales of radiology products, including 「オイパロミン注」, 「イオパーク注」, 「オプチレイ注」 and 「マグネスコープ静注」. - FY2018-Q1RestatedAnnual report
「In radiology, we are focusing on sales of the X-ray generic contrast agents 「オイパロミン注」 and 「イオパーク注」, which we have marketed for some time, 「オプチレイ注」, for which approval to add an indication was obtained last year, and the MRI contrast agent 「マグネスコープ静注」, among others.」
We continue to focus on sales of multiple contrast agents in radiology, including products for which additional indications have been approved. The consolidation of marketing rights and the end of the partnership will be recorded in a separate new thread. - FY2017AdvancedAnnual report
「In March 2017, we obtained approval to add computed tomography (CT) to the indications for the X-ray contrast agent 「オプチレイ注」 and began marketing the product.」
Describes the specific product rollout of 「オプチレイ注」, including approval to add a CT indication and the start of marketing. - FY2017-Q3RestatedAnnual report
「In addition to the generic contrast media we have sold previously, including Ioparomin injection and Iopark injection, and Optiray injection, a new X-ray contrast medium, we are focusing on sales of Magnescope injection, the most widely used MRI contrast medium in Europe, among other products.」
The Company continues to focus on sales of multiple contrast media products in the radiology area. - FY2017-Q2RestatedAnnual report
「In addition to the generic contrast media we have sold previously, including Ioparomin injection and Iopark injection, and Optiray injection, a new X-ray contrast medium, we are focusing on sales of Magnescope injection, the most widely used MRI contrast medium in Europe, among other products.」
The Company continues to focus on sales of multiple contrast media products in the radiology area. - FY2017-Q1RestatedAnnual report
「In addition to the generic contrast media we have sold previously, including Ioparomin injection and Iopark injection, and Optiray injection, a new X-ray contrast medium, we are focusing on sales of Magnescope injection, the most widely used MRI contrast medium in Europe, among other products.」
Lists multiple contrast media products in the radiology area and states that sales efforts remain a priority. - FY2016-Q3First statedAnnual report
「We are focusing on sales of Magnescope injection, the most widely used MRI contrast medium in Europe, among other products whose sales were transferred from Guerbet Japan Co., Ltd. in October 2015.」
Describes efforts to focus on sales of radiology products, including products transferred for sales.